Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
November 15, 2016
Assignees:
Icahn School of Medicine at Mount Sinai, Universitaet Duisberg-Essen, Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
Inventors:
Edward H. Schuchman, Erich Gulbins, Anthony Futerman, Yael Pewzner-Jung
Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
Type:
Grant
Filed:
October 1, 2010
Date of Patent:
November 18, 2014
Assignees:
Universität Duisberg Essen, Rheinische Friedrich Wilhelms —Universität Bonn
Inventors:
Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer, Edelgard Schneweis